Myeloid-derived suppressor cells in lymphoma: The good, the bad and the ugly. Issue 6 (November 2018)

• Record Type: Journal Article
• Authors: Betsch, A.; Rutgeerts, O.; Fevery, S.; Sprangers, B.; Verhoef, G.; Dierickx, D.; Beckers, M.
• Is Part Of: Blood reviews. Volume 32:Issue 6(2018:Nov.)
• Page Start: 490
• Page End: 498
• Publication Date: 2018-11
• Subjects: MDSC -- Lymphoma -- Immunotherapy; Hematology -- Periodicals; Hematology -- Periodicals; Hématologie -- Périodiques; Hematology; Electronic journals; Periodicals; 616.15
• DOI: 10.1016/j.blre.2018.04.006
• Languages: English
• ISSNs: 0268-960X

Abstract

Abstract: Lymphomas cause significant morbidity and mortality worldwide. A substantial number of patients ultimately relapse after standard treatment. However, the efficacy of these therapies can be counteracted by the patients' immune system, more specifically by myeloid-derived suppressor cells (MDSC). MDSC are a heterogeneous group of immature myeloid cells that suppress the innate and adaptive immune system via different mechanisms and accumulate under pathological conditions, such as cancer. MDSC play a role in the induction and progression of cancer and immune evasion. Increased numbers of MDSC have been reported in different lymphoma subtypes and are associated with a poor clinical outcome. This review aims to clarify the role of MDSC and their working mechanism in different lymphoma subtypes. Furthermore, the effect of MDSC on immunotherapies will be discussed.